Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

BAND Royalty is creating the only NFT Marketplace for Musicians

BAND Royalty has rolled out its first of four series of visionary NFT collectibles, granting them unique status by attaching them to potential revenue opportunities stemming from music artist royalties BAND’s stable of music royalty possibilities includes songs sung by artists such as Beyonce, Cher, Justin Timberlake, and Rihanna in its first series BAND’s art […]

SRAX Inc.’s (NASDAQ: SRAX) Premier Investor Real-Time Analytics Platform, Sequire, Helping 180+ Public Companies Track 5M+ Investors

SRAX’s Sequire SaaS platform provides tools to help public companies track shareholders, manage warrants, issue shareholder surveys SRAX recently featured in Wall Street Journal article highlighting volatility problems for public companies Sequire subscriber base doubled between Q3 and Q4 2020 to 183 public companies across 5 million+ active traders, investors SRAX (NASDAQ: SRAX), a financial […]

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Announces Status Report on Six Key R&D Programs

Lexaria announced significant strides in six of its studies within the 2021 applied R&D program All the studies are based on Lexaria’s DehydraTECH(TM) technology and are designed for multiple market applications, including oral nicotine, NSAIDs, antivirals, and hypertension The 2021 applied R&D program is intended to generate not only confirmatory results and data evidencing but […]

DealMaker Is ‘One to Watch’

Dealmaker boasts over three years in the market, with a consistent track record of triple-digit year-over-year growth and 30+ deals launched on its platform every month The company is committed to delivering transformational innovation to the capital markets Its robust, market leading technology is adaptable to client needs and strategically designed for growth into new […]

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significant milestone for the program Mescaline will form a critical component in XPhyto’s psychedelic medicine program […]

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Ships Initial Order of 0.5 Gram Vape Cartridges

Pure Extracts announced initial shipment of 0.5 gram vape cartridges to Alberta Gaming, Liquor & Cannabis CBD vape market has experienced strong growth in recent times, with one market research firm forecasting sector to be worth over $28bn by 2027 Pure Extracts has simultaneously sought to broaden its SKU’s within vape sector, commencing manufacture of […]

NASDAQ-Bound Sustainable Green Team Ltd. (SGTM) Offers Profitable Investment Opportunity Rooted in Sustainability

SGTM diverts storm-produced natural waste from landfills and transforms it into organic, environmentally-beneficial products Q1-2021 financial results show 16.7% YOY increase in revenue, 8.6% YOY increase in gross profit SGTM preparing for NASDAQ uplist, recently completed 2-year audit, commenced FORM-10 process to become fully reporting Before they realized massive financial success, the management at Sustainable […]

 

From Our Blog

Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care

September 28, 2026

For much of the last three decades, treatment of degenerative knee disease has centered heavily on managing symptoms with anti-inflammatories, activity modification, lubricants and injections, while structural intervention was often reserved for more advanced disease. Focal cartilage defects had surgical options, but those came with their own tradeoffs in durability, complexity, and cost. That balance […]

Rotate your device 90° to view site.